Learning Objectives:

1.Understand the potential risks and benefits of compounded GLP-1 receptor agonist therapies compared to FDA-approved options.

2.Evaluate the regulatory, legal, and ethical considerations of prescribing compounded peptides in the context of patient accessibility and affordability.

3.Equip clinicians with best practices for guiding patients who seek lower-cost, compounded alternatives for obesity treatment.